Challenges and Countermeasures of Integrative Cancer Therapy in the Epidemic of COVID-19
Identifieur interne : 000609 ( Pmc/Corpus ); précédent : 000608; suivant : 000610Challenges and Countermeasures of Integrative Cancer Therapy in the Epidemic of COVID-19
Auteurs : Geliang Yang ; Huiqing Zhang ; Yufei YangSource :
- Integrative Cancer Therapies [ 1534-7354 ] ; 2020.
Url:
DOI: 10.1177/1534735420912811
PubMed: 32178547
PubMed Central: 7079301
Links to Exploration step
PMC:7079301Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges and Countermeasures of Integrative Cancer Therapy in the
Epidemic of COVID-19</title><author><name sortKey="Yang, Geliang" sort="Yang, Geliang" uniqKey="Yang G" first="Geliang" last="Yang">Geliang Yang</name><affiliation><nlm:aff id="aff1-1534735420912811">Department of Traditional Chinese Medicine and Acupuncture, The Second Medical Centre, Chinese People Liberation Army General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, China</nlm:aff></affiliation></author><author><name sortKey="Zhang, Huiqing" sort="Zhang, Huiqing" uniqKey="Zhang H" first="Huiqing" last="Zhang">Huiqing Zhang</name><affiliation><nlm:aff id="aff2-1534735420912811">Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China</nlm:aff></affiliation></author><author><name sortKey="Yang, Yufei" sort="Yang, Yufei" uniqKey="Yang Y" first="Yufei" last="Yang">Yufei Yang</name><affiliation><nlm:aff id="aff3-1534735420912811">Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32178547</idno><idno type="pmc">7079301</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079301</idno><idno type="RBID">PMC:7079301</idno><idno type="doi">10.1177/1534735420912811</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000609</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000609</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Challenges and Countermeasures of Integrative Cancer Therapy in the
Epidemic of COVID-19</title><author><name sortKey="Yang, Geliang" sort="Yang, Geliang" uniqKey="Yang G" first="Geliang" last="Yang">Geliang Yang</name><affiliation><nlm:aff id="aff1-1534735420912811">Department of Traditional Chinese Medicine and Acupuncture, The Second Medical Centre, Chinese People Liberation Army General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, China</nlm:aff></affiliation></author><author><name sortKey="Zhang, Huiqing" sort="Zhang, Huiqing" uniqKey="Zhang H" first="Huiqing" last="Zhang">Huiqing Zhang</name><affiliation><nlm:aff id="aff2-1534735420912811">Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China</nlm:aff></affiliation></author><author><name sortKey="Yang, Yufei" sort="Yang, Yufei" uniqKey="Yang Y" first="Yufei" last="Yang">Yufei Yang</name><affiliation><nlm:aff id="aff3-1534735420912811">Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China</nlm:aff></affiliation></author></analytic><series><title level="j">Integrative Cancer Therapies</title><idno type="ISSN">1534-7354</idno><idno type="eISSN">1552-695X</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Chen, N" uniqKey="Chen N">N Chen</name></author><author><name sortKey="Zhou, M" uniqKey="Zhou M">M Zhou</name></author><author><name sortKey="Dong, X" uniqKey="Dong X">X Dong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, W" uniqKey="Liang W">W Liang</name></author><author><name sortKey="Guan, W" uniqKey="Guan W">W Guan</name></author><author><name sortKey="Chen, R" uniqKey="Chen R">R Chen</name></author></analytic></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="letter"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id><journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id><journal-id journal-id-type="publisher-id">ICT</journal-id><journal-id journal-id-type="hwp">spict</journal-id><journal-title-group><journal-title>Integrative Cancer Therapies</journal-title></journal-title-group><issn pub-type="ppub">1534-7354</issn><issn pub-type="epub">1552-695X</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32178547</article-id><article-id pub-id-type="pmc">7079301</article-id><article-id pub-id-type="doi">10.1177/1534735420912811</article-id><article-id pub-id-type="publisher-id">10.1177_1534735420912811</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Challenges and Countermeasures of Integrative Cancer Therapy in the
Epidemic of COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3878-2066</contrib-id><name><surname>Yang</surname><given-names>Geliang</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1-1534735420912811">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Huiqing</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff2-1534735420912811">2</xref><xref ref-type="corresp" rid="corresp1-1534735420912811"></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yufei</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff3-1534735420912811">3</xref><xref ref-type="corresp" rid="corresp1-1534735420912811"></xref></contrib></contrib-group><aff id="aff1-1534735420912811"><label>1</label>Department of Traditional Chinese Medicine and Acupuncture, The Second Medical Centre, Chinese People Liberation Army General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, China</aff><aff id="aff2-1534735420912811"><label>2</label>Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China</aff><aff id="aff3-1534735420912811"><label>3</label>Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China</aff><author-notes><corresp id="corresp1-1534735420912811">Prof. Huiqing Zhang, Department of
Traditional Chinese Medicine, Changhai Hospital, Naval Medical University.
Email: <email>newdew628@aliyun.com</email>; Prof. Yufei Yang, Department of
Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese
Medical Sciences. Email: <email>yyf93@vip.sina.com</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>19</volume><elocation-id>1534735420912811</elocation-id><permissions><copyright-statement>© The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2020</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>In December 2019, a novel coronavirus named COVID-19 outbroke in Wuhan, Hubei province,
and began spreading rapidly with more than 80 000 cases confirmed and 3000 deaths in
China. Italy, Iran, Korea, Japan, the United States, and other countries have reported
nearly 60 000 cases. Most COVID-19 patients initially suffered from fever, cough,
fatigue, and shortness of breath, while other symptoms included muscle pain, headache,
chest pain, and diarrhea, similar to the symptoms observed after chemotherapy, targeted
and immune therapy.<sup><xref rid="bibr1-1534735420912811" ref-type="bibr">1</xref></sup> In addition, cancer itself along with its treatment makes cancer patients more
susceptible to pneumonias, due to weakened immune response to respiratory bacteria and
virus. Thus, the epidemic spread of COVID-19 has posed great challenges to the clinical
practice of oncologists, especially for integrative cancer therapy.</p><p>According to the latest study revealing the correlation between COVID-19 and cancer, 18
(1%) of 1590 COVID-19 cases had a history of cancer, which was higher than the incidence
of cancer (0.29%) in the overall Chinese population; meanwhile, cancer patients were
found to have a higher risk of severe events than patients without cancer.<sup><xref rid="bibr2-1534735420912811" ref-type="bibr">2</xref></sup> We appeal to clinical oncologists to learn the diagnosis of COVID-19 well, and
cancer patients should be adequately screened for their epidemiological history,
especially for the travel to Wuhan and surrounding areas or other communities with
medical records, and respiratory and constitutional symptoms.</p><p>Generally speaking, anti-COVID-19 therapy should be prior to or combined with other
therapy, including anticancer treatment. Integrative cancer therapies such as
acupuncture and massage involve close contact with cancer patients, and are widely used
to relieve and control a variety of symptoms in cancer patients. We suggest that
integrative cancer therapies involving close contact with cancer patients should be
rigidly considered or forbidden in endemic areas, and stronger personal protection
provisions should be made for patients with cancer and integrative cancer therapists. In
high epidemic areas, members of the public are encouraged to reduce going out; thus, Tai
Chi and Qi Gong, as integrative therapies, might be very suitable indoor exercises to
strengthen the constitution.</p><p>To our best knowledge, there is still neither a vaccine nor specific antiviral drugs to
fight the COVID-19 infection, and current treatments mainly depend on therapy for
symptoms. In comparison, one integrative therapy, Chinese herbal medicine (CHM), is
widely used in the treatment of COVID-19, and was shown to be quite effective in
preliminary clinical practice. China’s National Health Commission issued a Diagnosis and
Treatment Protocol for COVID-19, providing a systemic treatment with CHM.<sup><xref rid="bibr3-1534735420912811" ref-type="bibr">3</xref></sup> Thus, cancer patients diagnosed with mild or medium COVID-19 should be encouraged
to receive CHM therapies. In addition, we should strengthen monitoring and give priority
to the patients infected with COVID-19 with cancer during CHM treatment, especially the
elderly and those with complications.</p><p>To better understand the treatment of COVID-19 and other severe infectious diseases, more
CHM clinical trials should be undertaken as soon as possible, and patients with cancer
history should be taken into consideration. We hope that our suggestions could help
better deal with challenges of integrative cancer therapy in the epidemic of
COVID-19.</p></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Geliang Yang <inline-graphic xlink:href="10.1177_1534735420912811-img1.jpg"></inline-graphic><ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-3878-2066">https://orcid.org/0000-0002-3878-2066</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1534735420912811"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal><article-title>Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: a descriptive study</article-title>. <source>Lancet</source>.
<year>2020</year>;<volume>395</volume>:<fpage>507</fpage>-<lpage>513</lpage>.<pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref><ref id="bibr2-1534735420912811"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal><article-title>Cancer patients in
SARS-CoV-2 infection: a nationwide analysis in China</article-title>[published online <month>2</month><day>14</day>, <year>2020</year>]. <source>Lancet Oncol</source>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(20)30096-6</pub-id></mixed-citation></ref><ref id="bibr3-1534735420912811"><label>3</label><mixed-citation publication-type="gov"><collab>General Office of the National Health Commission of China, General
Office of the State Administration of Traditional Chinese Medicine</collab>.
Diagnosis and treatment protocol for 2019-nCoV (Sixth Trial Edition). <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml">http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml</ext-link>.
Published <month>2</month><day>19</day>, <year>2020</year><comment>Accessed February 28,
2020</comment>.</mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000609 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000609 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7079301
|texte= Challenges and Countermeasures of Integrative Cancer Therapy in the
Epidemic of COVID-19
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32178547" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |